A programme for prevention and treatment of resistant hypertension with alqorithm based therapy. Pathway. Subcontract Univ Of Cambridge. BHF Award.

Webb, David (Principal Investigator)

Status	Finished
Effective start/end date	1/09/09 → 30/06/15

Funding

UK-based charities: £122,510.00

1 Article

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
forThe British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group, 1 Jun 2018, In: The Lancet Diabetes and Endocrinology. 6, 6, p. 464-475
Research output: Contribution to journal › Article › peer-review

Open Access
File